# Open access

1. Gloor GB, Macklaim JM, Pawlowsky-Glahn V, et al. Microbiome datasets are compositional: and this is not optional. Front Microbiol 2017;8:2224.
2. Martino C, Morton JT, Marotz CA, et al. A novel sparse compositional technique reveals microbial perturbations. mSystems 2019;4:e00016–19.
3. McMurdie PJ, Holmes S. phyloseq: an R package for reproducible interactive analysis and graphics of microbiome census data. PLoS One 2013;8:e61217.
4. Fernandes AD, Reid JN, Macklaim JM, et al. Unifying the analysis of high-throughput sequencing datasets: characterizing RNA-seq, 16S rRNA gene sequencing and selective growth experiments by compositional data analysis. Microbiome 2014;2:15.
5. Qu K, Guo F, Liu X, et al. Application of machine learning in microbiology. Front Microbiol 2019;10:827.
6. Camacho DM, Collins KM, Powers RK, et al. Next-Generation machine learning for biological networks. Cell 2018;173:1581–92.
7. Wishart DS, Tzur D, Knox C, et al. HMDB: the human metabolome database. Nucleic Acids Res 2007;35:D521–6.
8. Anderson CA, Boucher G, Lees CW, et al. Meta-Analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat Genet 2011;43:246–52.
9. Rivas MA, Avila BE, Koskela J, et al. Insights into the genetic epidemiology of Crohn’s and rare diseases in the Ashkenazi Jewish population. LoS Genet 2018;14:e1007329.
10. Huang H, Fang M, Jostins L, et al. Fine-Mapping inflammatory bowel disease loci to single-variant resolution. Nature 2017;547:173–8.
11. Cleynen I, Boucher G, Jostins L, et al. Inherited determinants of Crohn's disease and ulcerative colitis phenotypes: a genetic association study. Lancet 2016;387:156–67.
12. Goyette P, Boucher G, Mallon D, et al. High-Density mapping of the MHC identifies a shared role for HLA-DRB1*01:03 in inflammatory bowel diseases and heterozygous advantage in ulcerative colitis. Nat Genet 2015;47:172–9.
13. Vukcevic D, Traherne JA, Næss S, et al. Imputation of Kir types from SNP variation data. Am J Hum Genet 2015;97:593–607.
14. Gourraud P-A, Khankhanian P, Cereb N, et al. Hla diversity in the 1000 genomes dataset. PLoS One 2014;9:e97282.
15. Das S, Abecasis GR, Browning BL. Genotype imputation from large reference panels. Annu Rev Genomics Hum Genet 2018;19:73–96.
16. Ivison S, Des Rosiers C, Lesage S, et al. Biomarker-Guided stratification of autoimmune patients for biologic therapy. Curr Opin Immunol 2017;49:56–63.
17. Gao X, Song PX-K. Composite likelihood Bayesian information criteria for model selection in high-dimensional data. J Am Stat Assoc 2010;105:1531–40.
18. Lavis JN, Wilson MG, Grimshaw JM. Evidence brief: optimizing clinical practice in Ontario based on data, evidence and guidelines. Hamilton, Canada: McMaster Health Forum, 2015.
19. Wilson MG, Lavis JN. Dialogue summary: optimizing clinical practice in Ontario based on data, evidence and guidelines. Hamilton, Canada: McMaster Health Forum, 2015.
20. McIntosh K, Reed DE, Schneider T, et al. FODMAPs alter symptoms and the metabolome of patients with IBS: a randomised controlled trial. Gut 2017;66:1241–51.
21. Yilmaz B, Juillerat P, Øyås O, et al. Microbial network disturbances in relapsing refractory Crohn's disease. Nat Med 2019;25:323–36 https://doi.org/
22. Bercik P, Collins SM, Verdu EF. Microbes and the gut-brain axis. Neurogastroenterol Motil 2012;24:405–13.

MoayyedifiP, et al. BMJ Open 2020;10:e041733. doi:10.1136/bmjopen-2020-041733